Clinical Trials Directory

Trials / Completed

CompletedNCT04854642

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

Influence of Food on the Oral Bioavailability of Ladarixin 200 mg Capsule in Healthy Volunteers of Both Sexes. A Single Dose (400 mg), Randomized, Open Label, Two-Way Crossover Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Dompé Farmaceutici S.p.A · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

Primary objective: \- to investigate the effect of food on the bioavailability of DF 2156Y after single dose administration of 400 mg of ladarixin to healthy male and female volunteers under fed and fasting conditions. Secondary objectives: * to investigate the effect of gender on the bioavailability of DF 2156Y and its metabolites (DF 2108Y and DF 2227Y) after single dose administration of 400 mg of ladarixin to healthy male and female volunteers * to evaluate safety and tolerability of a single dose administration of ladarixin 400 mg to healthy male and female volunteers.

Detailed description

This is a Single center, single dose, open label, randomized, two-way, crossover, food effect on bioavailability study. More precisely, a single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.

Conditions

Interventions

TypeNameDescription
DRUGLadarixinA single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.

Timeline

Start date
2020-10-20
Primary completion
2020-12-09
Completion
2020-12-09
First posted
2021-04-22
Last updated
2024-01-17
Results posted
2022-01-11

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT04854642. Inclusion in this directory is not an endorsement.